Roche is the recipient of the new approval, getting the go-ahead from the US regulator for its PATHWAY HER2 (4B5) test to ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain ...

San Francisco-based Rad AI, which develops generative AI (GenAI) tools to improve radiology workflows, has raised $60 million ...

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...